Argenx Shares Down After Vyvgart Study Misses Primary Endpoint
28 11월 2023 - 9:03PM
Dow Jones News
By Dean Seal
Shares of Argenx dropped after the company said a study of its
treatment for primary immune thrombocytopenia didn't meet its
primary or secondary endpoints.
The stock fell 10% to $445 in premarket trading. Shares had
gained 31% year-to-date when the market closed Monday.
The immunology company said early Tuesday morning that its study
evaluating Vyvgart Hytrulo didn't meet the primary endpoint of a
sustained platelet count response in patients with chronic primary
immune thrombocytopenia, an autoimmune disorder.
"This is not the outcome we had hoped for patients," Chief
Medical Officer Luc Truyen said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 06:48 ET (11:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024